Genetic tumor PDL1 depletion suppresses pathologic tumor-intrinsic PDL1 signals and can improve the efficacy of cytotoxic agents and small molecules in distinct cancers [7,8,9,10], and genetic PDL1 cytoplasmic tail deletion in tumor cells heightens αPD1 ICB efficacy [11,12]. The gene discussed is CD274; the disease is cancer.